Literature DB >> 12051747

Structural characterization of a 2'F-RNA aptamer that binds a HIV-1 SU glycoprotein, gp120.

N Sayer1, J Ibrahim, K Turner, A Tahiri-Alaoui, W James.   

Abstract

Here we describe the isolation of specific 2'F-substituted RNA ligands for the SU glycoprotein, gp120, of HIV-1 strain HXB2. These aptamers bind the target protein with an affinity of the order of 10(-7) M. Binding was specific to SU glycoprotein and directed to a non-neutralizing epitope that was not shared with the related strain, HIV-1(BaL). The structure of one aptamer was defined by a combination of deletion analysis and enzymatic probing studies, revealing a 42 nt minimal element comprising a three-helix junction that retained the binding affinity of the parental sequence. Interestingly, binding to SU glycoprotein was accompanied by structural changes in the aptamer that stabilized the weakest of the 3 helices. (c) 2002 Elsevier Science (USA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12051747     DOI: 10.1016/S0006-291X(02)00308-X

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  18 in total

Review 1.  Cell-specific aptamer-mediated targeted drug delivery.

Authors:  Jiehua Zhou; John J Rossi
Journal:  Oligonucleotides       Date:  2010-12-23

2.  In vitro selection of RNA aptamers directed against protein E: a Haemophilus influenzae adhesin.

Authors:  Anders Barfod; Birendra Singh; Urban Johanson; Kristian Riesbeck; Per Kjellbom
Journal:  Mol Biotechnol       Date:  2014-08       Impact factor: 2.695

3.  UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype C.

Authors:  Hazel T Mufhandu; Elin S Gray; Maphuti C Madiga; Nancy Tumba; Kabamba B Alexandre; Thandeka Khoza; Constantinos Kurt Wibmer; Penny L Moore; Lynn Morris; Makobetsa Khati
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

Review 4.  Cell-type-specific aptamer and aptamer-small interfering RNA conjugates for targeted human immunodeficiency virus type 1 therapy.

Authors:  Jiehua Zhou; John Rossi
Journal:  J Investig Med       Date:  2014-10       Impact factor: 2.895

Review 5.  Aptamers as targeted therapeutics: current potential and challenges.

Authors:  Jiehua Zhou; John Rossi
Journal:  Nat Rev Drug Discov       Date:  2016-11-03       Impact factor: 84.694

6.  An aptamer that neutralizes R5 strains of human immunodeficiency virus type 1 blocks gp120-CCR5 interaction.

Authors:  Antu K Dey; Makobetsa Khati; Min Tang; Richard Wyatt; Susan M Lea; William James
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

7.  Aptamer-targeted cell-specific RNA interference.

Authors:  Jiehua Zhou; John J Rossi
Journal:  Silence       Date:  2010-02-01

Review 8.  Therapeutic potential of aptamer-siRNA conjugates for treatment of HIV-1.

Authors:  Jiehua Zhou; John J Rossi
Journal:  BioDrugs       Date:  2012-12-01       Impact factor: 5.807

9.  Neutralization of infectivity of diverse R5 clinical isolates of human immunodeficiency virus type 1 by gp120-binding 2'F-RNA aptamers.

Authors:  Makobetsa Khati; Michael Schüman; Jamal Ibrahim; Quentin Sattentau; Siamon Gordon; William James
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

10.  Protection of HIV neutralizing aptamers against rectal and vaginal nucleases: implications for RNA-based therapeutics.

Authors:  Michael D Moore; Jonathan Cookson; Veronica K Coventry; Brian Sproat; Lorna Rabe; Ross D Cranston; Ian McGowan; William James
Journal:  J Biol Chem       Date:  2010-11-24       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.